English
Regional settings| Spread | 0.0256 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 2.1122 |
| Open | 2.1322 |
| 1-Year Change | -36.25% |
| Day's Range | 2.1322 - 2.1422 |
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments. The Company's technologies include the CyberKnife and TomoTherapy platforms, including the Radixact System. The CyberKnife and TomoTherapy platform, which are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
BRIEF: For the six months ended 31 December 2021, Accuray Incorporated revenues increased 22% to $223.7M. Net loss totaled $849K vs. income of $5.2M. Revenues reflect Product segment increase of 55% to $113.5M, Service segment increase of less than 1% to $110.2M, China (Country) segment increase of 98% to $49.2M, Americas segment increase of 37% to $75M. Net loss reflects Research and development increase of 21% to $28.4M (expense).
Common Stock, $.001 Par, 12/10, 100M auth., 61,865,443 issd., less 2,140,018 shs. in Treas. @ Cost. Insiders own 2.14%. IPO: 2/07, 16M shs. @ $18 per share by JPMorgan, UBS Investment Bank, Piper Jaffray, Jefferies & Co.
